American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 59-65.e1 , July 2009

Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study

  • Ziad F. Bashshur

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • Corresponding Author InformationInquiries to Ziad F. Bashshur, American University of Beirut—Medical Center, P. O. Box 11-0236/B11, Beirut, Lebanon
    • ,
  • Zeina A. Haddad

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • ,
  • Alexandre R. Schakal

      Affiliations

    • Department of Ophthalmology, Hotel Dieu de France, St Joseph University, Beirut, Lebanon
    • ,
  • Rola F. Jaafar

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • ,
  • Alain Saad

      Affiliations

    • Department of Ophthalmology, Hotel Dieu de France, St Joseph University, Beirut, Lebanon
    • ,
  • Baha' N. Noureddin

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon

,Accepted 3 February 2009.

References 

  1. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352–368
  2. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multi-dose study. Ophthalmology. 2006;113:633–642
  3. Rosenfeld PJ, Brown DM, Heier JS, et al. Marina Study Group Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1419–1431
  4. Brown DM, Kaiser PK, Michels M, et al. Anchor Study Group Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1432–1444
  5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable-dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–583
  6. Mulcahy MF, Benson AB. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005;5:997–1005
  7. Rosenfeld PJ, Moshfghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascularization age-related macular degeneration. Ophthalmic Surg Laser Imaging. 2005;36:331–335
  8. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: 12-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047
  9. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1–9
  10. Spaide RF, Laud K, Fine H, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390
  11. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495–511
  12. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372
  13. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to Lucentis?. Am J Ophthalmol. 2006;142:141–143
  14. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–1412
  15. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249–256
  16. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335–345
  17. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124:175–189
  18. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina. 2008;28:1387–1394
  19. Ton NC, Jayson GC. Resistance to anti-VEGF agents. Curr Pharmaceut Des. 2004;10:51–64
  20. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974
  21. Abdollahi A, Klatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 2005;8:59–74
  22. Van Kempen LC, Leenders WP. Tumors can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. Eur J Cell Biol. 2006;85:61–68
  23. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859
  24. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508–512
  25. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–1349
  26. Van Wijngaarden P, Coster D, Williams K. Inhibitors of ocular neovascularization promises and potential problems. JAMA. 2005;293:1509–1513
  27. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?. Ophthalmology. 2008;115:2199–2205
  28. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol. 2008;92:1636–1641

 See accompanying Editorial on page 1.

PII: S0002-9394(09)00103-2

doi: 10.1016/j.ajo.2009.02.006

American Journal of Ophthalmology
Volume 148, Issue 1 , Pages 59-65.e1 , July 2009

Article Tools

* Image Usage & Resolution